On 26-28 April 2010, the second conference on Strategies agains Counterfeit Medicine was organised in Heidelberg, Germany.
The conference informed about the implementation of Counterfeit Protection Systems in the pharmaceutical industry.

Objectives

The aim of this conference was to present both the regulatory authorities' activities and the pharmaceutical industry's activities to develop and establish appropriate counterfeit protection systems. The conference focused on effective and affordable strategies, collaboration among regulators and pharmaceutical industry, and discussions about actions in the global fight against counterfeit were held.

Speakers

• Nimo Ahmed,
  MHRA, UK
• Patricia Blanco,
  ETCO, Brazil
• Hugo Bonar,
  Irish Medicines Board, Ireland
• Andy Charvill,
  MHRA, UK
• Frederick L. Fricke,
  FDA, USA
• Jean-Michel Guirado,
  Amgen, The Netherlands
• Prof Dr. Ulrike Holzgrabe,
  University of Würzburg, Germany
• Dr Dries de Kaste,
  RIVM, The Netherlands
• Dr Sabine Kopp,
  WHO, Switzerland
• Dr Thomas Lenhard,
  sanofi-aventis, Germany
• Dr Chris Oldenhof,
  DSM Anti-Infectives, The Netherlands
• Dr Jim Rittenburg,
  Authentix Inc., USA
• Dr Stephan Schwarze,
  Bayer Schering Pharma AG, Germany
• Janice M. Soreth,
  FDA, USA
• Nathalie Tallet,
  sanofi-aventis, France
• Dr Christian Tillmanns,
  meyer//meisterernst Rechtsanwälte, Germany

Highlights

• Regulatory Updates
  - WHO’s Anticounterfeiting
    Programme and IMPACT
  - EU Directive on Counterfeit and
    the Council of Europe’s Draft
    Convention
  - MHRA (UK) Anticounterfeiting
    Strategy
  - FDA’s Activities
  - Legal Obligations and Implications
    for the Pharmaceutical Industry
• The Pharmaceutical Tracing and Authentication System in Brazil
• Analytical Detection of Counterfeit Drugs
  - Advanced Forensic Techniques at FDA’s
    Forensic Chemistry Center
  - Role of the MHRA (UK) Anticounterfeiting
    Laboratory
  - NIR and Raman Spectroscopy at the RIVM
    (NL) Laboratory
  - Missions and Role of Sanofi-Aventis’
    Testing Laboratory

• Falsified APIs: Are we solving the problems?
• Experiences from EFPIA’s Pilot in Sweden for Coding and Identification with 2D Data Matrix Code
• Supply Chain Integrity
• Means, Measures and Tools to Protect a Pharmaceutical Product

 
 
 
 Exclusive media partner:

 

 
[ imprint ]